Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 612345...Last »

Pernix Cuts 22 Percent of Workforce in Reorganization

Pernix Therapeutics is undergoing a reorganization that includes the termination of a number of sales representatives.

Read More »

Pfizer Axes 3 Drugs From Pipeline in Q1 2017

In Pfizer’s first-quarter 2017 financial report, total revenue was down 2 percent year over year. The company also reported three discontinued pipeline projects.

Read More »

AbbVie profit beats on Humira demand

AbbVie Inc. reported a larger-than-expected first-quarter 2017 profit, lifted by demand for the company’s flagship drug Humira.

Read More »

AstraZeneca Dumps Two Drugs From Pipeline

As AstraZeneca faces declining revenue in 2017 from the loss of patents and the challenge of generic drugs, the company culled two drugs from its pipeline.

Read More »

Covance Cuts 100+ Employees in Shut Down

Princeton, N.J.-based CRO Covance plans to shutter its lab in Evansville, Ind., in summer 2017. More than 100 staffers are expected to be laid off.

Read More »

Novartis sets sights on return to growth in 2018

Novartis reported better-than-expected first-quarter 2017 profits with CEO Joe Jimenez remaining confident the Swiss drugmaker would return to growth in 2018.

Read More »

Biogen profit beats analysts’ estimates

Biogen Inc.’s first-quarter 2017 profit blew past analysts’ estimates, helped by higher-than-expected sales of its recently launched spinal muscular atrophy drug Spinraza.

Read More »

J&J first-quarter 2017 revenue misses estimates

Johnson & Johnson reported disappointing pharmaceutical and consumer product sales for first-quarter 2017 as revenue missed analyst estimates.

Read More »

Sanofi sees possibility of lower earnings in 2017

Sanofi expected 2017 EPS to be stable or slightly lower after its fourth-quarter 2016 results were affected by an increase in taxes and one-off charges.

Read More »

Merck 2017 forecast eases analyst concerns

Merck & Co. Inc. reported better-than-expected U.S. quarterly sales for its key cancer drug Keytruda and forecast largely in-line 2017 results.

Read More »

Bone Therapeutics Taps New CEO

Shares of Bone Therapeutics dropped slightly after the company announced a change in leadership and ended plans to hold a clinical trial in the United States.

Read More »

Gilead Racks Up Clinical Failures in Q3 Report

Investors were not particularly happy with Gilead’s Q3 2016 report. In addition to sagging sales and revenue, it outlined a laundry list of failed clinical trials.

Read More »

Biogen Quietly Kills Autoimmune Program

While there were definitely positive items in Biogen’s third-quarter 2016 report, the company also threw in what almost seemed like an afterthought – it was no longer developing amiselimod (MT-1303).

Read More »

Abbott’s third-quarter earnings edge past Street

Abbott Laboratories reported a quarterly profit that edged past estimates as strength in its medical devices business more than offset a decline in its nutrition unit.

Read More »

Novo Nordisk cuts forecasts on tough U.S. market

Novo Nordisk cut its forecast for full-year 2016 profit growth and said it expected tough competition in the United States to pressure prices in 2017.

Read More »

Pfizer beats estimates; branded drugs disappoint

Pfizer Inc. reported better-than-expected second-quarter 2016 results, but revenue from its branded patent-protected medicines brought disappointment.

Read More »

Sanofi 2Q sales and profit slide

Sanofi’s quarterly sales and profit fell despite double-digit growth at biotech arm Genzyme as the diabetes division came under sustained U.S. pricing pressure.

Read More »

Bristol-Myers shares hit by decline of Yervoy

Bristol-Myers Squibb reported disappointing 2Q 2016 sales of its Yervoy melanoma treatment.

Read More »

Sales of Revlimid drive Celgene profit

Celgene Corp. exceeded expectations for second-quarter 2016 earnings on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines.

Read More »

AstraZeneca Kills Six Pipeline Programs

Along with its dismal half-year financial reports, UK-based AstraZeneca announced it was halting six pipeline programs.

Read More »

Page 1 of 612345...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation